Companies / SPL

STARPHARMA HOLDINGS LIMITED

ASX:SPLPharmaceuticals, Biotechnology & Life Sciences
420.9M shares on issueASX (delayed) · as of 28 July 2026$0.69price · delayed$290.4Mmarket cap · indicative
B
Dilution grade

1 cash raise in 24 months; options/rights overhang 10% of shares; proposed issue pending

Cash runway12.9 quarters of funding
Share-count growth (24m)2.1%
Raise cadence (24m)1 cash raise
Options & rights overhang9.9% of shares
In-the-money supply0.0% of shares
Pending proposed issuesopen proposed issue (Appendix 3B)

STARPHARMA HOLDINGS LIMITED's ordinary share count was 421M as of April 2026, up 2.1% since July 2024. The company completed one capital raise in the 24‑month window, an Entitlement Offer in July 2026 raising A$32.0M (total proceeds A$32.0M). Options and rights on issue could convert into 42M new shares, equal to 9.9% of the current share count, of which 0% are in the money. At the June 2026 quarter the company reported A$42.0M in cash, covering 12.9 quarters at its recent spend rate. One proposed securities issue (Appendix 3B) is pending with an expected issue date in August 2026.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
9.9%
Max option dilution
0.0%
ITM option dilution
1
Raises · last 12 months
12.9 qtrs
Cash cover · over 4 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 420.9M per ASX (delayed) (28 July 2026).
418.7M419.5M420.3MDec 24Sept 25July 26Cash raise · 15 July 2026

Cash runway

12.9 qtrs
More than four quarters of funding at the recent spend rate.
$42.0M available cash at quarter ended 30 June 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 30 June 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
6 Apr 20262A · quoted issueSPL : ORDINARY FULLY PAID420.9MAppendix 2A
7 Jan 20263H · cancellationSPL : ORDINARY FULLY PAID418.2MAppendix 3H
7 Jan 20262A · quoted issueSPL : ORDINARY FULLY PAID419.9MAppendix 2A
17 Dec 20253G · unquotedORDINARY FULLY PAID418.2MAppendix 3G
5 Oct 20253H · cancellationSPL : ORDINARY FULLY PAID418.2MAppendix 3H
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

1 cash raise in the last 24 months · 1 in the last 12 months

$32.0M
Entitlement Offer
15 July 2026 ACTIVE
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

1 proposed issue pending — Appendix 3B lodged, securities not yet issued. New shares from these issues are not in the counts above until quoted.
Paid plan
Pending issue detail
Size, price, fees, broker and placement-capacity usage for each pending issue.
Join the waitlist

Options & convertible securities

9.9%
Total overhang · of current shares
0.0%
In the money · at current price
41.8M
Potential new shares
—
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
12 Dec 2025Cheryl MaleyOther———3Y notice
16 Oct 2025Robert B. ThomasBuy450k—$125k3Y notice
30 Sept 2025Cheryl MaleySell125k——3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

23 July 2026Letter to Ineligible Shareholders
23 July 2026Letter to Eligible Shareholders
21 July 2026Ceasing to be a substantial holder
16 July 2026Entitlement Offer Booklet
14 July 2026Cleansing Notice
14 July 2026Proposed issue of securities - SPL
14 July 2026$PEntitlement Offer Investor Presentation
14 July 2026$PFully Underwritten Entitlement Offer to Raise $32 Million
14 July 2026$PQuarterly Activities Report and Appendix 4C
7 July 2026DEP HER2 Investor Webinar
2 July 2026$PDEP milestone triggers partner option fee
1 July 2026$PPositive DEP HER2-Lu preclinical data support Phase 1 entry
1 July 2026$PDEP radiopharmaceutical data supports patent application
23 June 2026Becoming a substantial holder
16 June 2026Becoming a substantial holder
29 Apr 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
20 Apr 2026$PFDA confirms path to DEP HER2 first-in-human study
14 Apr 2026Becoming a substantial holder
6 Apr 2026Application for quotation of securities - SPL
12 Mar 2026Ceasing to be a substantial holder

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.